Marlon Ramilo, MD
Cardiovascular Disease · Modesto, CANPI 1659316412
Payments from drug & device makers
Across 1,037 payments — averaging $478.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$208K
- Merck$149K
- Johnson & Johnson$91K
- Bayer$17K
- Novartis$9K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$8K
- plus $16K from 30 others
What the payments were for
- Consulting fees$7750%
- Speaking & faculty fees$386,93878%
- Travel & lodging$78,66816%
- Food & beverage$29,6186%
- Education$2980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 170 | $207,653 |
| Merck | 154 | $148,516 |
| Johnson & Johnson | 166 | $91,125 |
| Bayer | 133 | $17,146 |
| Novartis | 34 | $8,590 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $7,598 |
| Abbott | 91 | $5,011 |
| E.r. Squibb & Sons, L.L.C. | 54 | $1,707 |
| Abiomed | 13 | $1,096 |
| Amgen | 40 | $992 |
| United Therapeutics Corporation | 33 | $980 |
| AstraZeneca | 19 | $655 |
| Boehringer Ingelheim | 15 | $546 |
| Actelion Pharmaceuticals US, Inc. | 14 | $484 |
| Akcea Therapeutics, Inc. | 5 | $471 |
| Medtronic(2 entities) | 7 | $448 |
| Biotronik Inc. | 6 | $394 |
| Lilly USA, LLC | 5 | $335 |
| Esperion Therapeutics, Inc. | 7 | $331 |
| Boston Scientific | 4 | $321 |
| Vifor Pharma, Inc. | 2 | $299 |
| Shockwave Medical, Inc | 2 | $260 |
| Sanofi-aventis U.S. LLC | 6 | $244 |
| Sobi, Inc | 1 | $150 |
| Atricure, Inc. | 1 | $137 |
| Regeneron Healthcare Solutions, Inc. | 5 | $132 |
| Mylan Specialty L.p. | 6 | $127 |
| Cardiovascular Systems Inc. | 2 | $124 |
| Scpharmaceuticals Inc. | 4 | $122 |
| Astellas Pharma US Inc | 1 | $92 |
| Pfizer | 3 | $66 |
| Edwards Lifesciences | 3 | $60 |
| Gilead | 2 | $48 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$496,298 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 55 | $773,262 |
| Tyvaso DpiTreprostinil | 21 | $538,283 |
| XareltoRivaroxaban | 288 | $306,970 |
| UptraviSelexipag | 11 | $256,509 |
| VerquvoVericiguat | 135 | $172,987 |
| LetairisAmbrisentan | 13 | $169,121 |
| OpsumitMacitentan | 13 | $162,163 |
| OzempicSemaglutide | 89 | $128,611 |
| EntrestoSacubitril/Valsartan | 97 | $119,879 |
| EliquisApixaban | 108 | $118,142 |
| JardianceEmpagliflozin | 98 | $113,132 |
| Repatha SureclickEvolocumab | 138 | $103,717 |
| RybelsusSemaglutide | 54 | $67,189 |
| FarxigaDapagliflozin Propanediol | 40 | $45,703 |
| BrilintaTicagrelor | 40 | $29,873 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $17,146 | $773,26255 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $484 | $418,67224 claims |
| Johnson & JohnsonXarelto | $91,125 | $306,970288 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $207,653 | $209,917154 claims |
| MerckVerquvo | $148,516 | $172,987135 claims |
| GileadLetairis | $48 | $169,12113 claims |
| NovartisEntresto | $8,590 | $119,87997 claims |
| PfizerEliquis | $66 | $118,142108 claims |
| Boehringer IngelheimJardiance | $546 | $113,13298 claims |
| AstraZenecaFarxiga, Brilinta | $655 | $75,57680 claims |
| Esperion Therapeutics, Inc.Nexlizet | $331 | $17,46415 claims |
| Lilly USA, LLCTrulicity | $335 | $9,95212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Modesto
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.